Neuromuscular Disease News

In patients with neuromyelitis optica spectrum disorder, transition from rituximab to inebilizumab was linked to suppression of attacks over a mean 19 months of treatment, according to research published in Frontiers in Neurology.

DENVER — A combination therapy of ciprofloxacin and celecoxib demonstrated a favorable safety profile for those with amyotrophic lateral sclerosis, Merit Cudkowicz, MD, MSc, said in this Healio video.

The FDA has granted breakthrough therapy designation to a proprietary oligonucleotide conjugate for the treatment of myotonic dystrophy type 1, according to the manufacturer.

DENVER — Experiences and concerns about treatment, diagnosis, care, cost and quality of life among Black and Hispanic patients with myasthenia gravis were more negative compared with their Asian and white counterparts, according to research.

DENVER — Losmapimod treatment for those with facioscapulohumeral muscular dystrophy led to no serious adverse events across three clinical trials, according to a poster at the American Academy of Neurology annual meeting.

The FDA has granted regenerative medicine advanced therapy designation to an intrathecally delivered AAV9 gene transfer therapy to treat younger individuals with Rett syndrome, according to the manufacturer.

DENVER — A panel of four experts discussed different aspects of the ways brain health and climate change are linked at the American Academy of Neurology annual meeting.

DENVER — Uncontrolled generalized myasthenia negatively affects patients’ mental health, which in turn negatively impacts their physical symptoms, according to a poster presentation at the American Academy of Neurology annual meeting.

Wearable accelerometers may be a reliable tool to track disease progression in patients with amyotrophic lateral sclerosis, researchers wrote in The Lancet.

The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive dyskinesia, according to a press release from the manufacturer.